Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression

Journal of Translational Medicine

Volumn 15, Issue 1, 2017, Pages

  Mfarrej, Bechara ^a   Tresoldi, Eleonora ^a,b   Stabilini, Angela ^a   Paganelli, Alessia ^a   Caldara, Rossana ^a   Secchi, Antonio ^a   Battaglia, Manuela ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Cell therapy; Clinical grade compatible protocol; Kidney transplantation; Tolerance induction

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; GAMMA INTERFERON; INTERLEUKIN 10; LIPOPOLYSACCHARIDE RECEPTOR; TRANSCRIPTOME;

ARTICLE; CELL THERAPY; CONTROLLED STUDY; CRYOPRESERVATION; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; REGULATORY T LYMPHOCYTE; T REGULATORY TYPE 1 CELL; CELL PROLIFERATION; DENDRITIC CELL; DONOR; IMMUNOLOGY; METABOLISM; MONOCYTE; REPRODUCIBILITY; TIME FACTOR;

CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; KIDNEY TRANSPLANTATION; LEUKAPHERESIS; LIPOPOLYSACCHARIDE RECEPTORS; MONOCYTES; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TISSUE DONORS; TRANSCRIPTOME;

EID: 85013448421     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-017-1133-8     Document Type: Article

References (21)

1. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr Top Microbiol Immunol. 2014;380:39-68.
2. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+T cells. J Exp Med. 1996;184(1):19-29.
3. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 2010;116(6):935-44.
4. Bacchetta R, Lucarelli B, Sartirana C, Gregori S, Lupo Stanghellini MT, Miqueu P, et al. Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells. Front Immunol. 2014;5:16.
5. Geissler EK, The ONE. Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells. Transplant Res. 2012;1(1):11.
6. Petrelli A, Tresoldi E, Mfarrej BG, Paganelli A, Spotti D, Caldara R, et al. Generation of donor-specific T regulatory type 1 cells from patients on dialysis for cell therapy after kidney transplantation. Transplantation. 2015;99(8):1582-9.
7. Bacchetta R, Gregori S, Serafini G, Sartirana C, Schulz U, Zino E, et al. Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. Haematologica. 2010;95(12):2134-43.
8. Petrelli A, Tresoldi E, Mfarrej BG, Paganelli A, Spotti D, Caldara R, et al. Generation of donor-specific T regulatory type 1 cells from patients on dialysis for cell therapy after kidney transplantation. Transplantation. 2015;99:1582-9.
9. Meyer-Wentrup F, Burdach S. Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+starting populations. J Hematother Stem Cell Res. 2003;12(3):289-99.
10. Babatz J, Röllig C, Oelschlägel U, Zhao S, Ehninger G, Schmitz M, et al. Large-scale immunomagnetic selection of CD14+monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res. 2003;12(5):515-23.
11. Singh G. Determination of cutoff score for a diagnostic test. Internet J Lab Med. 2006. http://ispub.com/IJLM/2/1/9884. Accessed 9 Jan 2016.
12. Gagliani N, Jofra T, Stabilini A, Valle A, Atkinson M, Roncarolo MG, et al. Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes. 2010;59(2):433-9.
13. Thurner B, Röder C, Dieckmann D, Heuer M, Kruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223(1):1-15.
14. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013;19(6):739-46.
15. Brusko TM, Hulme MA, Myhr CB, Haller MJ, Atkinson MA. Assessing the in vitro suppressive capacity of regulatory T cells. Immunol Invest. 2007;36(5-6):607-28.
16. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 depletion, Treg expansion, and Treg cryopreservation. PLoS ONE. 2008;3(9):e3161.
17. Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, et al. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013;16(3):371-5.
18. Trzonkowski P, Bacchetta R, Battaglia M, Berglund D, Bohnenkamp HR, tenBrinke A, et al. Hurdles in therapy with regulatory T cells. Sci Transl Med. 2015;7(304):304-18.
19. Tchao NK, Turka LA. Lymphodepletion and homeostatic proliferation: implications for transplantation. Am J Transpl. 2012;12(5):1079-90.
20. Strasser EF, Eckstein R. Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. Transfus Med Rev. 2010;24(2):130-9.
21. Scottà C, Fanelli G, Hoong SJ, Romano M, Lamperti EN, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101(1):91-100.